Home » Posts tagged 'MUKUND GURJAR'
Tag Archives: MUKUND GURJAR
EMCURE-A SUCESS STORY
Mukund K Gurjar
| Emcure Pharmaceuticals Limited | ||
| ITBT Park Phase II | ||
| Hinjwadi, PUNE, INDIA |
Among the vast ocean of literature on organic chemistry , you will find a pearl in the form of Emcure
we are treated to excellent reading material and important communications in our field
hats off to this team


Dr. Mukund K. Gurjar serves as the Chief Scientific Officer of Emcure Pharmaceuticals Limited and serves as its Director of Research & Development.
Dr. Gurjar has been closely associated with Drugs and Pharmaceutical Sciences since 1975 and is a distinguished Researcher in the country. He has carried out extensive work in the field of new chemical entities (NCEs). Dr. Gurjar has been an Executive Director of Emcure Pharmaceuticals Ltd. since 2001.
He serves as Deputy Director at National Chemical Laboratory, Pune. Dr. Gurjar served as Non-Executive Director of Cipla Limited since January 19, 2002 until August 27, 2007.
Dr. Gurjar has the distinction of being one of the 43 scientists from India who have been mentioned in the Institute of Scientific Information of Chemists and has more than 500 citations. Dr. Gurjar has obtained Master of Science degree in Organic Chemistry and Ph.D. in chemistry from the Nagpur University. He also obtained the second Ph.D. degree from the London University, UK.
He is a leading Fellow at various National and International Academies
Board Members Memberships
Education
Other Affiliations

LINKS
http://www.emcure.co.in/bod.asp
http://www.ias.ac.in/php/fell_detail.php3?name=Gurjar&intials=Mukund&year=28-08-1952
http://www.researchgate.net/profile/Mukund_Gurjar/
| About EMCURE : Company Profile as quoted by COMPANY WEBSITE |
|
The Company was incorporated as Emcure Pharmaceuticals Private Limited on April 16, 1981 as a private limited company under the Companies Act, 1956.Emcure Pharmaceuticals is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Our core strength lies in developing and manufacturing differentiated pharmaceutical products in-house, which we commercialize through our marketing infrastructure across geographies and relationships with multi-national pharmaceutical companies.Emcure Pharmaceuticals is ranked as the 14th largest pharmaceutical company (Source: IMS Health India, Secondary Stockist Audit (“SSA”), March 2013) in India in terms of market share based on the domestic sales of pharmaceutical products. We believe that our competitive advantage in the domestic market lies in our established presence in all major therapeutic areas including blood related, cardiology, pain and analgesics, HIV, gynecology, nephrology, anti-infective, and vitamins, minerals and nutrients products. We have also recently entered the oncology and diabetes therapeutic areas.Emcure Pharmaceuticals have a well-diversified income base thanks to our business in the international markets. We have our own sales and marketing infrastructure in the United States through our subsidiary, Heritage. We sell our portfolio of branded generic products to the Rest of World. Our products are currently shipped to over 65 countries, where we have established our presence by focusing on important alliances with local and multi-national companies that enjoy a leadership position in the therapeutic areas on which we focus. We have subsidiaries in Dubai, Brazil, South Africa, Singapore and Nigeria and branch offices in Russia and Morocco.Emcure Pharmaceuticals…….quote………. are focus our research and development efforts on developing a portfolio of differentiated products across several platforms, including chiral molecules and biosimilars, and novel drug delivery systems. We have a portfolio of 11 chiral molecules, eight of which we launched for the first time in India. We also have capabilities to develop complex products, including difficult iron preparations, oncology drugs and controlled release products. Our portfolio of in-house manufactured five commercialized biosimilars including TNK-tPA, which we launched for the first time in India, and our brand Vintor is ranked no. 1 in erythropoietin market (Epoetin Alfa Recombinant) (Source: IMS Health India, SSA, March 2013).
|
..

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....










